#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=The number of males diagnosed with prostate cancer ( PCa ) is increasing all over the world .
1-1	0-3	The	abstract[1]	new[1]	_	_
1-2	4-10	number	abstract[1]	new[1]	_	_
1-3	11-13	of	abstract[1]	new[1]	_	_
1-4	14-19	males	abstract[1]|person[2]	new[1]|new[2]	_	_
1-5	20-29	diagnosed	abstract[1]|person[2]	new[1]|new[2]	_	_
1-6	30-34	with	abstract[1]|person[2]	new[1]|new[2]	_	_
1-7	35-43	prostate	abstract[1]|person[2]|place|abstract[4]	new[1]|new[2]|new|new[4]	appos|coref	1-10[0_4]|4-20
1-8	44-50	cancer	abstract[1]|person[2]|abstract[4]	new[1]|new[2]|new[4]	_	_
1-9	51-52	(	_	_	_	_
1-10	53-56	PCa	abstract	giv	coref	2-4[8_0]
1-11	57-58	)	_	_	_	_
1-12	59-61	is	_	_	_	_
1-13	62-72	increasing	_	_	_	_
1-14	73-76	all	place[6]	new[6]	_	_
1-15	77-81	over	place[6]	new[6]	_	_
1-16	82-85	the	place[6]	new[6]	_	_
1-17	86-91	world	place[6]	new[6]	_	_
1-18	92-93	.	_	_	_	_

#Text=Most patients with early-stage PCa can be treated by the appropriate therapy , such as radical prostatectomy or irradiation .
2-1	94-98	Most	person[7]	new[7]	coref	3-19[17_7]
2-2	99-107	patients	person[7]	new[7]	_	_
2-3	108-112	with	person[7]	new[7]	_	_
2-4	113-124	early-stage	person[7]|abstract[8]	new[7]|giv[8]	coref	3-21[18_8]
2-5	125-128	PCa	person[7]|abstract[8]	new[7]|giv[8]	_	_
2-6	129-132	can	_	_	_	_
2-7	133-135	be	_	_	_	_
2-8	136-143	treated	_	_	_	_
2-9	144-146	by	_	_	_	_
2-10	147-150	the	abstract[9]	new[9]	coref	3-6[14_9]
2-11	151-162	appropriate	abstract[9]	new[9]	_	_
2-12	163-170	therapy	abstract[9]	new[9]	_	_
2-13	171-172	,	abstract[9]	new[9]	_	_
2-14	173-177	such	abstract[9]	new[9]	_	_
2-15	178-180	as	abstract[9]	new[9]	_	_
2-16	181-188	radical	abstract[9]|object[10]	new[9]|new[10]	_	_
2-17	189-202	prostatectomy	abstract[9]|object[10]	new[9]|new[10]	_	_
2-18	203-205	or	abstract[9]	new[9]	_	_
2-19	206-217	irradiation	abstract[9]|abstract	new[9]|new	_	_
2-20	218-219	.	_	_	_	_

#Text=On the other hand , androgen deprivation therapy ( ADT ) is the standard systemic therapy given to patients with advanced PCa .
3-1	220-222	On	_	_	_	_
3-2	223-226	the	_	_	_	_
3-3	227-232	other	_	_	_	_
3-4	233-237	hand	_	_	_	_
3-5	238-239	,	_	_	_	_
3-6	240-248	androgen	abstract|abstract[14]	new|giv[14]	appos|coref	3-10[0_14]|5-11
3-7	249-260	deprivation	abstract|abstract[14]	new|giv[14]	_	_
3-8	261-268	therapy	abstract[14]	giv[14]	_	_
3-9	269-270	(	_	_	_	_
3-10	271-274	ADT	abstract	giv	coref	3-13[16_0]
3-11	275-276	)	_	_	_	_
3-12	277-279	is	_	_	_	_
3-13	280-283	the	abstract[16]	giv[16]	coref	4-1[0_16]
3-14	284-292	standard	abstract[16]	giv[16]	_	_
3-15	293-301	systemic	abstract[16]	giv[16]	_	_
3-16	302-309	therapy	abstract[16]	giv[16]	_	_
3-17	310-315	given	abstract[16]	giv[16]	_	_
3-18	316-318	to	abstract[16]	giv[16]	_	_
3-19	319-327	patients	abstract[16]|person[17]	giv[16]|giv[17]	coref	4-7[21_17]
3-20	328-332	with	abstract[16]|person[17]	giv[16]|giv[17]	_	_
3-21	333-341	advanced	abstract[16]|person[17]|abstract[18]	giv[16]|giv[17]|giv[18]	coref	4-19[24_18]
3-22	342-345	PCa	abstract[16]|person[17]|abstract[18]	giv[16]|giv[17]|giv[18]	_	_
3-23	346-347	.	_	_	_	_

#Text=ADT induces temporary remission , but the majority of patients ( approximately 60 % ) eventually progress to castration-resistant prostate cancer ( CRPC ) , which is associated with a high mortality rate .
4-1	348-351	ADT	abstract	giv	coref	6-6
4-2	352-359	induces	_	_	_	_
4-3	360-369	temporary	event[20]	new[20]	_	_
4-4	370-379	remission	event[20]	new[20]	_	_
4-5	380-381	,	_	_	_	_
4-6	382-385	but	_	_	_	_
4-7	386-389	the	person[21]	giv[21]	coref	17-32[149_21]
4-8	390-398	majority	person[21]	giv[21]	_	_
4-9	399-401	of	person[21]	giv[21]	_	_
4-10	402-410	patients	person[21]	giv[21]	_	_
4-11	411-412	(	_	_	_	_
4-12	413-426	approximately	abstract[22]	new[22]	_	_
4-13	427-429	60	abstract[22]	new[22]	_	_
4-14	430-431	%	abstract[22]	new[22]	_	_
4-15	432-433	)	_	_	_	_
4-16	434-444	eventually	_	_	_	_
4-17	445-453	progress	abstract	new	coref|none	9-2[59_0]|4-17[0_59]
4-18	454-456	to	_	_	_	_
4-19	457-477	castration-resistant	abstract[24]	giv[24]	appos	4-23[0_24]
4-20	478-486	prostate	place|abstract[24]	giv|giv[24]	coref	11-37
4-21	487-493	cancer	abstract[24]	giv[24]	_	_
4-22	494-495	(	_	_	_	_
4-23	496-500	CRPC	abstract	giv	coref	5-4
4-24	501-502	)	_	_	_	_
4-25	503-504	,	_	_	_	_
4-26	505-510	which	_	_	_	_
4-27	511-513	is	_	_	_	_
4-28	514-524	associated	_	_	_	_
4-29	525-529	with	_	_	_	_
4-30	530-531	a	abstract[27]	new[27]	_	_
4-31	532-536	high	abstract[27]	new[27]	_	_
4-32	537-546	mortality	event|abstract[27]	new|new[27]	_	_
4-33	547-551	rate	abstract[27]	new[27]	_	_
4-34	552-553	.	_	_	_	_

#Text=Generally , well-differentiated PCa cells are androgen-dependent , i.e. , androgen receptor ( AR ) signaling regulates cell cycle and differentiation .
5-1	554-563	Generally	_	_	_	_
5-2	564-565	,	_	_	_	_
5-3	566-585	well-differentiated	animal[29]	new[29]	coref	6-12[43_29]
5-4	586-589	PCa	abstract|animal[29]	giv|new[29]	coref	6-16
5-5	590-595	cells	animal[29]	new[29]	_	_
5-6	596-599	are	_	_	_	_
5-7	600-618	androgen-dependent	_	_	_	_
5-8	619-620	,	_	_	_	_
5-9	621-625	i.e.	_	_	_	_
5-10	626-627	,	_	_	_	_
5-11	628-636	androgen	abstract|substance[31]|abstract[33]	giv|new[31]|new[33]	coref	6-3[39_33]
5-12	637-645	receptor	substance[31]|abstract[33]	new[31]|new[33]	_	_
5-13	646-647	(	abstract[33]	new[33]	_	_
5-14	648-650	AR	abstract|abstract[33]	new|new[33]	coref	6-3
5-15	651-652	)	abstract[33]	new[33]	_	_
5-16	653-662	signaling	abstract[33]	new[33]	_	_
5-17	663-672	regulates	_	_	_	_
5-18	673-677	cell	place|abstract[35]	new|new[35]	_	_
5-19	678-683	cycle	abstract[35]	new[35]	_	_
5-20	684-687	and	_	_	_	_
5-21	688-703	differentiation	event	new	_	_
5-22	704-705	.	_	_	_	_

#Text=Loss of AR signaling after ADT triggers androgen-independent outgrowth , generating poorly differentiated , uncontrollable PCa cells .
6-1	706-710	Loss	event[37]	new[37]	_	_
6-2	711-713	of	event[37]	new[37]	_	_
6-3	714-716	AR	event[37]|abstract|abstract[39]	new[37]|giv|giv[39]	coref|coref	8-28|15-21[128_39]
6-4	717-726	signaling	event[37]|abstract[39]	new[37]|giv[39]	_	_
6-5	727-732	after	event[37]	new[37]	_	_
6-6	733-736	ADT	event[37]|abstract	new[37]|giv	coref	7-8
6-7	737-745	triggers	_	_	_	_
6-8	746-766	androgen-independent	event[41]	new[41]	_	_
6-9	767-776	outgrowth	event[41]	new[41]	_	_
6-10	777-778	,	_	_	_	_
6-11	779-789	generating	_	_	_	_
6-12	790-796	poorly	animal[43]	giv[43]	coref	7-2[45_43]
6-13	797-811	differentiated	animal[43]	giv[43]	_	_
6-14	812-813	,	animal[43]	giv[43]	_	_
6-15	814-828	uncontrollable	animal[43]	giv[43]	_	_
6-16	829-832	PCa	abstract|animal[43]	giv|giv[43]	coref	7-2
6-17	833-838	cells	animal[43]	giv[43]	_	_
6-18	839-840	.	_	_	_	_

#Text=Once PCa cells lose their sensitivity to ADT , effective therapies are limited .
7-1	841-845	Once	_	_	_	_
7-2	846-849	PCa	abstract|animal[45]	giv|giv[45]	ana|coref	7-5[0_45]|8-16
7-3	850-855	cells	animal[45]	giv[45]	_	_
7-4	856-860	lose	_	_	_	_
7-5	861-866	their	animal|abstract[47]	giv|new[47]	coref	17-11[143_0]
7-6	867-878	sensitivity	abstract[47]	new[47]	_	_
7-7	879-881	to	abstract[47]	new[47]	_	_
7-8	882-885	ADT	abstract[47]|abstract	new[47]|giv	_	_
7-9	886-887	,	_	_	_	_
7-10	888-897	effective	abstract[49]	new[49]	_	_
7-11	898-907	therapies	abstract[49]	new[49]	_	_
7-12	908-911	are	_	_	_	_
7-13	912-919	limited	_	_	_	_
7-14	920-921	.	_	_	_	_

#Text=In the last few years , however , several new options for the treatment of CRPC have been approved , e.g. , the CYP17 inhibitor , the AR antagonist , and the taxane .
8-1	922-924	In	_	_	_	_
8-2	925-928	the	time[50]	new[50]	coref	12-10[92_50]
8-3	929-933	last	time[50]	new[50]	_	_
8-4	934-937	few	time[50]	new[50]	_	_
8-5	938-943	years	time[50]	new[50]	_	_
8-6	944-945	,	_	_	_	_
8-7	946-953	however	_	_	_	_
8-8	954-955	,	_	_	_	_
8-9	956-963	several	abstract[51]	new[51]	_	_
8-10	964-967	new	abstract[51]	new[51]	_	_
8-11	968-975	options	abstract[51]	new[51]	_	_
8-12	976-979	for	abstract[51]	new[51]	_	_
8-13	980-983	the	abstract[51]|abstract[52]	new[51]|new[52]	coref	10-17[0_52]
8-14	984-993	treatment	abstract[51]|abstract[52]	new[51]|new[52]	_	_
8-15	994-996	of	abstract[51]|abstract[52]	new[51]|new[52]	_	_
8-16	997-1001	CRPC	abstract[51]|abstract[52]|abstract	new[51]|new[52]|giv	coref	13-25
8-17	1002-1006	have	_	_	_	_
8-18	1007-1011	been	_	_	_	_
8-19	1012-1020	approved	_	_	_	_
8-20	1021-1022	,	_	_	_	_
8-21	1023-1027	e.g.	abstract[55]	new[55]	_	_
8-22	1028-1029	,	abstract[55]	new[55]	_	_
8-23	1030-1033	the	abstract[55]	new[55]	_	_
8-24	1034-1039	CYP17	substance|abstract[55]	new|new[55]	_	_
8-25	1040-1049	inhibitor	abstract[55]	new[55]	_	_
8-26	1050-1051	,	_	_	_	_
8-27	1052-1055	the	person[57]	new[57]	_	_
8-28	1056-1058	AR	abstract|person[57]	giv|new[57]	coref	15-21
8-29	1059-1069	antagonist	person[57]	new[57]	_	_
8-30	1070-1071	,	_	_	_	_
8-31	1072-1075	and	_	_	_	_
8-32	1076-1079	the	animal[58]	new[58]	_	_
8-33	1080-1086	taxane	animal[58]	new[58]	_	_
8-34	1087-1088	.	_	_	_	_

#Text=Despite this progress in the development of new drugs , there is a high medical need for optimizing the sequence and combination of approved drugs .
9-1	1089-1096	Despite	_	_	_	_
9-2	1097-1101	this	abstract[59]	new[59]	_	_
9-3	1102-1110	progress	abstract[59]	new[59]	_	_
9-4	1111-1113	in	abstract[59]	new[59]	_	_
9-5	1114-1117	the	abstract[59]|event[60]	new[59]|new[60]	_	_
9-6	1118-1129	development	abstract[59]|event[60]	new[59]|new[60]	_	_
9-7	1130-1132	of	abstract[59]|event[60]	new[59]|new[60]	_	_
9-8	1133-1136	new	abstract[59]|event[60]|substance[61]	new[59]|new[60]|new[61]	coref	9-24[65_61]
9-9	1137-1142	drugs	abstract[59]|event[60]|substance[61]	new[59]|new[60]|new[61]	_	_
9-10	1143-1144	,	_	_	_	_
9-11	1145-1150	there	_	_	_	_
9-12	1151-1153	is	_	_	_	_
9-13	1154-1155	a	abstract[62]	new[62]	_	_
9-14	1156-1160	high	abstract[62]	new[62]	_	_
9-15	1161-1168	medical	abstract[62]	new[62]	_	_
9-16	1169-1173	need	abstract[62]	new[62]	_	_
9-17	1174-1177	for	abstract[62]	new[62]	_	_
9-18	1178-1188	optimizing	abstract[62]	new[62]	_	_
9-19	1189-1192	the	abstract[62]|abstract[63]	new[62]|new[63]	_	_
9-20	1193-1201	sequence	abstract[62]|abstract[63]	new[62]|new[63]	_	_
9-21	1202-1205	and	abstract[62]	new[62]	_	_
9-22	1206-1217	combination	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-23	1218-1220	of	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-24	1221-1229	approved	abstract[62]|abstract[64]|substance[65]	new[62]|new[64]|giv[65]	_	_
9-25	1230-1235	drugs	abstract[62]|abstract[64]|substance[65]	new[62]|new[64]|giv[65]	_	_
9-26	1236-1237	.	_	_	_	_

#Text=Thus , identification of predictive biomarkers may help in the context of personalized medicine to guide treatment decisions , improve clinical outcomes , and prevent unnecessary side effects .
10-1	1238-1242	Thus	_	_	_	_
10-2	1243-1244	,	_	_	_	_
10-3	1245-1259	identification	abstract[66]	new[66]	_	_
10-4	1260-1262	of	abstract[66]	new[66]	_	_
10-5	1263-1273	predictive	abstract[66]|abstract[67]	new[66]|new[67]	_	_
10-6	1274-1284	biomarkers	abstract[66]|abstract[67]	new[66]|new[67]	_	_
10-7	1285-1288	may	_	_	_	_
10-8	1289-1293	help	_	_	_	_
10-9	1294-1296	in	_	_	_	_
10-10	1297-1300	the	abstract[68]	new[68]	_	_
10-11	1301-1308	context	abstract[68]	new[68]	_	_
10-12	1309-1311	of	abstract[68]	new[68]	_	_
10-13	1312-1324	personalized	abstract[68]|abstract[69]	new[68]|new[69]	coref	11-28[0_69]
10-14	1325-1333	medicine	abstract[68]|abstract[69]	new[68]|new[69]	_	_
10-15	1334-1336	to	_	_	_	_
10-16	1337-1342	guide	_	_	_	_
10-17	1343-1352	treatment	abstract|abstract[71]	giv|new[71]	_	_
10-18	1353-1362	decisions	abstract[71]	new[71]	_	_
10-19	1363-1364	,	_	_	_	_
10-20	1365-1372	improve	_	_	_	_
10-21	1373-1381	clinical	abstract[72]	new[72]	_	_
10-22	1382-1390	outcomes	abstract[72]	new[72]	_	_
10-23	1391-1392	,	_	_	_	_
10-24	1393-1396	and	_	_	_	_
10-25	1397-1404	prevent	_	_	_	_
10-26	1405-1416	unnecessary	abstract[73]	new[73]	_	_
10-27	1417-1421	side	abstract[73]	new[73]	_	_
10-28	1422-1429	effects	abstract[73]	new[73]	_	_
10-29	1430-1431	.	_	_	_	_

#Text=Departments of Nephro-Urologic Surgery and Andrology ( Professor Emeritus Yoshiki Sugimura ) and Oncologic Pathology ( Professor Emeritus Taizo Shiraishi ) , Mie University Graduate School of Medicine , organized the semi-closed symposium on Biology of Prostate Gland Ise-Shima .
11-1	1432-1443	Departments	organization[74]	new[74]	appos	11-23[83_74]
11-2	1444-1446	of	organization[74]	new[74]	_	_
11-3	1447-1462	Nephro-Urologic	organization[74]|object|abstract[76]	new[74]|new|new[76]	_	_
11-4	1463-1470	Surgery	organization[74]|abstract[76]	new[74]|new[76]	_	_
11-5	1471-1474	and	organization[74]	new[74]	_	_
11-6	1475-1484	Andrology	organization[74]|abstract	new[74]|new	_	_
11-7	1485-1486	(	organization[74]	new[74]	_	_
11-8	1487-1496	Professor	organization[74]|person[78]	new[74]|new[78]	appos	11-17[80_78]
11-9	1497-1505	Emeritus	organization[74]|person[78]	new[74]|new[78]	_	_
11-10	1506-1513	Yoshiki	organization[74]|person[78]	new[74]|new[78]	_	_
11-11	1514-1522	Sugimura	organization[74]|person[78]	new[74]|new[78]	_	_
11-12	1523-1524	)	organization[74]	new[74]	_	_
11-13	1525-1528	and	organization[74]	new[74]	_	_
11-14	1529-1538	Oncologic	organization[74]|abstract[79]	new[74]|new[79]	_	_
11-15	1539-1548	Pathology	organization[74]|abstract[79]	new[74]|new[79]	_	_
11-16	1549-1550	(	_	_	_	_
11-17	1551-1560	Professor	person[80]	giv[80]	_	_
11-18	1561-1569	Emeritus	person[80]	giv[80]	_	_
11-19	1570-1575	Taizo	person[80]	giv[80]	_	_
11-20	1576-1585	Shiraishi	person[80]	giv[80]	_	_
11-21	1586-1587	)	_	_	_	_
11-22	1588-1589	,	_	_	_	_
11-23	1590-1593	Mie	person|organization[83]	new|giv[83]	_	_
11-24	1594-1604	University	organization|organization[83]	new|giv[83]	_	_
11-25	1605-1613	Graduate	organization[83]	giv[83]	_	_
11-26	1614-1620	School	organization[83]	giv[83]	_	_
11-27	1621-1623	of	organization[83]	giv[83]	_	_
11-28	1624-1632	Medicine	organization[83]|abstract	giv[83]|giv	coref	17-24[147_0]
11-29	1633-1634	,	_	_	_	_
11-30	1635-1644	organized	_	_	_	_
11-31	1645-1648	the	event[85]	new[85]	coref	12-1[90_85]
11-32	1649-1660	semi-closed	event[85]	new[85]	_	_
11-33	1661-1670	symposium	event[85]	new[85]	_	_
11-34	1671-1673	on	event[85]	new[85]	_	_
11-35	1674-1681	Biology	event[85]|abstract[86]	new[85]|new[86]	_	_
11-36	1682-1684	of	event[85]|abstract[86]	new[85]|new[86]	_	_
11-37	1685-1693	Prostate	event[85]|abstract[86]|place|place[88]	new[85]|new[86]|giv|new[88]	coref	13-22
11-38	1694-1699	Gland	event[85]|abstract[86]|place[88]	new[85]|new[86]|new[88]	_	_
11-39	1700-1709	Ise-Shima	event[85]|abstract[86]|abstract	new[85]|new[86]|new	_	_
11-40	1710-1711	.	_	_	_	_

#Text=This symposium was started in 2002 and was held every four years in 2006 , 2010 , 2014 , and 2018 without any financial support from pharmaceutical companies and chemical industries .
12-1	1712-1716	This	event[90]	giv[90]	coref	13-4[102_90]
12-2	1717-1726	symposium	event[90]	giv[90]	_	_
12-3	1727-1730	was	_	_	_	_
12-4	1731-1738	started	_	_	_	_
12-5	1739-1741	in	_	_	_	_
12-6	1742-1746	2002	time	new	_	_
12-7	1747-1750	and	_	_	_	_
12-8	1751-1754	was	_	_	_	_
12-9	1755-1759	held	_	_	_	_
12-10	1760-1765	every	time[92]	giv[92]	_	_
12-11	1766-1770	four	time[92]	giv[92]	_	_
12-12	1771-1776	years	time[92]	giv[92]	_	_
12-13	1777-1779	in	_	_	_	_
12-14	1780-1784	2006	time	new	_	_
12-15	1785-1786	,	_	_	_	_
12-16	1787-1791	2010	time	new	_	_
12-17	1792-1793	,	_	_	_	_
12-18	1794-1798	2014	time	new	_	_
12-19	1799-1800	,	_	_	_	_
12-20	1801-1804	and	_	_	_	_
12-21	1805-1809	2018	time	new	coref	16-13
12-22	1810-1817	without	_	_	_	_
12-23	1818-1821	any	abstract[97]	new[97]	_	_
12-24	1822-1831	financial	abstract[97]	new[97]	_	_
12-25	1832-1839	support	abstract[97]	new[97]	_	_
12-26	1840-1844	from	abstract[97]	new[97]	_	_
12-27	1845-1859	pharmaceutical	abstract[97]|organization[98]	new[97]|new[98]	_	_
12-28	1860-1869	companies	abstract[97]|organization[98]	new[97]|new[98]	_	_
12-29	1870-1873	and	abstract[97]	new[97]	_	_
12-30	1874-1882	chemical	abstract[97]|substance|organization[100]	new[97]|new|new[100]	_	_
12-31	1883-1893	industries	abstract[97]|organization[100]	new[97]|new[100]	_	_
12-32	1894-1895	.	_	_	_	_

#Text=Each year , the symposium was attended by 40 – 50 Japanese investigators with expertise and interest in biology of the prostate gland and PCa .
13-1	1896-1900	Each	time[101]	new[101]	_	_
13-2	1901-1905	year	time[101]	new[101]	_	_
13-3	1906-1907	,	_	_	_	_
13-4	1908-1911	the	event[102]	giv[102]	coref	14-4[112_102]
13-5	1912-1921	symposium	event[102]	giv[102]	_	_
13-6	1922-1925	was	_	_	_	_
13-7	1926-1934	attended	_	_	_	_
13-8	1935-1937	by	_	_	_	_
13-9	1938-1940	40	person[103]	new[103]	_	_
13-10	1941-1942	–	person[103]	new[103]	_	_
13-11	1943-1945	50	person[103]	new[103]	_	_
13-12	1946-1954	Japanese	person[103]	new[103]	_	_
13-13	1955-1968	investigators	person[103]	new[103]	_	_
13-14	1969-1973	with	person[103]	new[103]	_	_
13-15	1974-1983	expertise	person[103]|abstract|abstract[105]	new[103]|new|new[105]	coref|coref	18-15|18-15[157_105]
13-16	1984-1987	and	person[103]|abstract[105]	new[103]|new[105]	_	_
13-17	1988-1996	interest	person[103]|abstract[105]|abstract[106]	new[103]|new[105]|new[106]	coref	18-17[158_106]
13-18	1997-1999	in	person[103]|abstract[105]|abstract[106]	new[103]|new[105]|new[106]	_	_
13-19	2000-2007	biology	person[103]|abstract[105]|abstract[106]|abstract[107]	new[103]|new[105]|new[106]|new[107]	_	_
13-20	2008-2010	of	person[103]|abstract[105]|abstract[106]|abstract[107]	new[103]|new[105]|new[106]|new[107]	_	_
13-21	2011-2014	the	person[103]|abstract[105]|abstract[106]|abstract[107]|substance[109]	new[103]|new[105]|new[106]|new[107]|new[109]	_	_
13-22	2015-2023	prostate	person[103]|abstract[105]|abstract[106]|abstract[107]|place|substance[109]	new[103]|new[105]|new[106]|new[107]|giv|new[109]	_	_
13-23	2024-2029	gland	person[103]|abstract[105]|abstract[106]|abstract[107]|substance[109]	new[103]|new[105]|new[106]|new[107]|new[109]	_	_
13-24	2030-2033	and	person[103]|abstract[105]|abstract[106]|abstract[107]	new[103]|new[105]|new[106]|new[107]	_	_
13-25	2034-2037	PCa	person[103]|abstract[105]|abstract[106]|abstract[107]|abstract	new[103]|new[105]|new[106]|new[107]|giv	coref	14-30
13-26	2038-2039	.	_	_	_	_

#Text=The goal of this symposium was to discuss the biological mechanism of the development and progression of prostatic proliferative diseases such as benign prostatic hyperplasia ( BPH ) and PCa .
14-1	2040-2043	The	abstract[111]	new[111]	_	_
14-2	2044-2048	goal	abstract[111]	new[111]	_	_
14-3	2049-2051	of	abstract[111]	new[111]	_	_
14-4	2052-2056	this	abstract[111]|event[112]	new[111]|giv[112]	coref	16-10[137_112]
14-5	2057-2066	symposium	abstract[111]|event[112]	new[111]|giv[112]	_	_
14-6	2067-2070	was	_	_	_	_
14-7	2071-2073	to	_	_	_	_
14-8	2074-2081	discuss	_	_	_	_
14-9	2082-2085	the	abstract[113]	new[113]	_	_
14-10	2086-2096	biological	abstract[113]	new[113]	_	_
14-11	2097-2106	mechanism	abstract[113]	new[113]	_	_
14-12	2107-2109	of	abstract[113]	new[113]	_	_
14-13	2110-2113	the	abstract[113]|event[114]	new[113]|new[114]	_	_
14-14	2114-2125	development	abstract[113]|event[114]	new[113]|new[114]	_	_
14-15	2126-2129	and	abstract[113]	new[113]	_	_
14-16	2130-2141	progression	abstract[113]|event[115]	new[113]|new[115]	coref	15-24[130_115]
14-17	2142-2144	of	abstract[113]|event[115]	new[113]|new[115]	_	_
14-18	2145-2154	prostatic	abstract[113]|event[115]|abstract[116]	new[113]|new[115]|new[116]	_	_
14-19	2155-2168	proliferative	abstract[113]|event[115]|abstract[116]	new[113]|new[115]|new[116]	_	_
14-20	2169-2177	diseases	abstract[113]|event[115]|abstract[116]	new[113]|new[115]|new[116]	_	_
14-21	2178-2182	such	abstract[113]|event[115]|abstract[116]	new[113]|new[115]|new[116]	_	_
14-22	2183-2185	as	abstract[113]|event[115]|abstract[116]	new[113]|new[115]|new[116]	_	_
14-23	2186-2192	benign	abstract[113]|event[115]|abstract[116]|abstract[117]	new[113]|new[115]|new[116]|new[117]	appos	14-27[0_117]
14-24	2193-2202	prostatic	abstract[113]|event[115]|abstract[116]|abstract[117]	new[113]|new[115]|new[116]|new[117]	_	_
14-25	2203-2214	hyperplasia	abstract[113]|event[115]|abstract[116]|abstract[117]	new[113]|new[115]|new[116]|new[117]	_	_
14-26	2215-2216	(	_	_	_	_
14-27	2217-2220	BPH	abstract	giv	coref	15-13
14-28	2221-2222	)	_	_	_	_
14-29	2223-2226	and	_	_	_	_
14-30	2227-2230	PCa	abstract	giv	coref	15-19
14-31	2231-2232	.	_	_	_	_

#Text=Several major topic areas were discussed , e.g. , the pathophysiology of BPH , the tumor microenvironment of PCa , AR signaling in PCa progression , and the development of PCa detection and diagnosis .
15-1	2233-2240	Several	abstract[121]	new[121]	_	_
15-2	2241-2246	major	abstract[121]	new[121]	_	_
15-3	2247-2252	topic	abstract|abstract[121]	new|new[121]	_	_
15-4	2253-2258	areas	abstract[121]	new[121]	_	_
15-5	2259-2263	were	_	_	_	_
15-6	2264-2273	discussed	_	_	_	_
15-7	2274-2275	,	_	_	_	_
15-8	2276-2280	e.g.	abstract[122]	new[122]	_	_
15-9	2281-2282	,	abstract[122]	new[122]	_	_
15-10	2283-2286	the	abstract[122]	new[122]	_	_
15-11	2287-2302	pathophysiology	abstract[122]	new[122]	_	_
15-12	2303-2305	of	abstract[122]	new[122]	_	_
15-13	2306-2309	BPH	abstract[122]|abstract	new[122]|giv	_	_
15-14	2310-2311	,	_	_	_	_
15-15	2312-2315	the	abstract[125]	new[125]	_	_
15-16	2316-2321	tumor	object|abstract[125]	new|new[125]	_	_
15-17	2322-2338	microenvironment	abstract[125]	new[125]	_	_
15-18	2339-2341	of	abstract[125]	new[125]	_	_
15-19	2342-2345	PCa	abstract[125]|abstract	new[125]|giv	coref	15-24
15-20	2346-2347	,	_	_	_	_
15-21	2348-2350	AR	abstract|abstract[128]	giv|giv[128]	_	_
15-22	2351-2360	signaling	abstract[128]	giv[128]	_	_
15-23	2361-2363	in	abstract[128]	giv[128]	_	_
15-24	2364-2367	PCa	abstract[128]|abstract|event[130]	giv[128]|giv|giv[130]	coref	15-31
15-25	2368-2379	progression	abstract[128]|event[130]	giv[128]|giv[130]	_	_
15-26	2380-2381	,	_	_	_	_
15-27	2382-2385	and	_	_	_	_
15-28	2386-2389	the	event[131]	new[131]	_	_
15-29	2390-2401	development	event[131]	new[131]	_	_
15-30	2402-2404	of	event[131]	new[131]	_	_
15-31	2405-2408	PCa	event[131]|abstract|abstract[133]	new[131]|giv|new[133]	coref	17-12
15-32	2409-2418	detection	event[131]|abstract[133]	new[131]|new[133]	_	_
15-33	2419-2422	and	event[131]	new[131]	_	_
15-34	2423-2432	diagnosis	event[131]|abstract	new[131]|new	_	_
15-35	2433-2434	.	_	_	_	_

#Text=This Special Issue includes the major topics discussed at the symposium in 2018 .
16-1	2435-2439	This	abstract[135]	new[135]	coref	17-2[139_135]
16-2	2440-2447	Special	abstract[135]	new[135]	_	_
16-3	2448-2453	Issue	abstract[135]	new[135]	_	_
16-4	2454-2462	includes	_	_	_	_
16-5	2463-2466	the	abstract[136]	new[136]	_	_
16-6	2467-2472	major	abstract[136]	new[136]	_	_
16-7	2473-2479	topics	abstract[136]	new[136]	_	_
16-8	2480-2489	discussed	abstract[136]	new[136]	_	_
16-9	2490-2492	at	abstract[136]	new[136]	_	_
16-10	2493-2496	the	abstract[136]|event[137]	new[136]|giv[137]	_	_
16-11	2497-2506	symposium	abstract[136]|event[137]	new[136]|giv[137]	_	_
16-12	2507-2509	in	abstract[136]|event[137]	new[136]|giv[137]	_	_
16-13	2510-2514	2018	abstract[136]|event[137]|time	new[136]|giv[137]|giv	_	_
16-14	2515-2516	.	_	_	_	_

#Text=In this Special Issue , we focused on cytobiology of human PCa cells and its clinical applications to develop a major step towards personalized medicine matched to the individual needs of patients with early-stage and advanced PCa and CRPC .
17-1	2517-2519	In	_	_	_	_
17-2	2520-2524	this	abstract[139]	giv[139]	coref	18-4[153_139]
17-3	2525-2532	Special	abstract[139]	giv[139]	_	_
17-4	2533-2538	Issue	abstract[139]	giv[139]	_	_
17-5	2539-2540	,	_	_	_	_
17-6	2541-2543	we	person	acc	ana	18-1
17-7	2544-2551	focused	_	_	_	_
17-8	2552-2554	on	_	_	_	_
17-9	2555-2566	cytobiology	abstract[141]	new[141]	ana	17-15[0_141]
17-10	2567-2569	of	abstract[141]	new[141]	_	_
17-11	2570-2575	human	abstract[141]|animal[143]	new[141]|giv[143]	coref	18-22[161_143]
17-12	2576-2579	PCa	abstract[141]|abstract|animal[143]	new[141]|giv|giv[143]	coref	17-34[150_0]
17-13	2580-2585	cells	abstract[141]|animal[143]	new[141]|giv[143]	_	_
17-14	2586-2589	and	_	_	_	_
17-15	2590-2593	its	abstract|abstract[145]	giv|new[145]	coref	18-26[164_145]
17-16	2594-2602	clinical	abstract[145]	new[145]	_	_
17-17	2603-2615	applications	abstract[145]	new[145]	_	_
17-18	2616-2618	to	_	_	_	_
17-19	2619-2626	develop	_	_	_	_
17-20	2627-2628	a	abstract[146]	new[146]	_	_
17-21	2629-2634	major	abstract[146]	new[146]	_	_
17-22	2635-2639	step	abstract[146]	new[146]	_	_
17-23	2640-2647	towards	abstract[146]	new[146]	_	_
17-24	2648-2660	personalized	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
17-25	2661-2669	medicine	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
17-26	2670-2677	matched	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
17-27	2678-2680	to	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
17-28	2681-2684	the	abstract[146]|abstract[147]|abstract[148]	new[146]|giv[147]|new[148]	_	_
17-29	2685-2695	individual	abstract[146]|abstract[147]|abstract[148]	new[146]|giv[147]|new[148]	_	_
17-30	2696-2701	needs	abstract[146]|abstract[147]|abstract[148]	new[146]|giv[147]|new[148]	_	_
17-31	2702-2704	of	abstract[146]|abstract[147]|abstract[148]	new[146]|giv[147]|new[148]	_	_
17-32	2705-2713	patients	abstract[146]|abstract[147]|abstract[148]|person[149]	new[146]|giv[147]|new[148]|giv[149]	_	_
17-33	2714-2718	with	abstract[146]|abstract[147]|abstract[148]|person[149]	new[146]|giv[147]|new[148]|giv[149]	_	_
17-34	2719-2730	early-stage	abstract[146]|abstract[147]|abstract[148]|person[149]|abstract[150]	new[146]|giv[147]|new[148]|giv[149]|giv[150]	coref	17-39[0_150]
17-35	2731-2734	and	abstract[146]|abstract[147]|abstract[148]|person[149]|abstract[150]	new[146]|giv[147]|new[148]|giv[149]|giv[150]	_	_
17-36	2735-2743	advanced	abstract[146]|abstract[147]|abstract[148]|person[149]|abstract[150]	new[146]|giv[147]|new[148]|giv[149]|giv[150]	_	_
17-37	2744-2747	PCa	abstract[146]|abstract[147]|abstract[148]|person[149]|abstract[150]	new[146]|giv[147]|new[148]|giv[149]|giv[150]	_	_
17-38	2748-2751	and	abstract[146]|abstract[147]|abstract[148]|person[149]	new[146]|giv[147]|new[148]|giv[149]	_	_
17-39	2752-2756	CRPC	abstract[146]|abstract[147]|abstract[148]|person[149]|abstract	new[146]|giv[147]|new[148]|giv[149]|giv	coref	18-23
17-40	2757-2758	.	_	_	_	_

#Text=We hope that this Special Issue attracts a lot of attention for readers with expertise and interest in the cytobiology of human PCa cells and its clinical applications .
18-1	2759-2761	We	person	giv	_	_
18-2	2762-2766	hope	_	_	_	_
18-3	2767-2771	that	_	_	_	_
18-4	2772-2776	this	abstract[153]	giv[153]	_	_
18-5	2777-2784	Special	abstract[153]	giv[153]	_	_
18-6	2785-2790	Issue	abstract[153]	giv[153]	_	_
18-7	2791-2799	attracts	_	_	_	_
18-8	2800-2801	a	abstract[154]	new[154]	_	_
18-9	2802-2805	lot	abstract[154]	new[154]	_	_
18-10	2806-2808	of	abstract[154]	new[154]	_	_
18-11	2809-2818	attention	abstract[154]	new[154]	_	_
18-12	2819-2822	for	_	_	_	_
18-13	2823-2830	readers	person[155]	new[155]	_	_
18-14	2831-2835	with	person[155]	new[155]	_	_
18-15	2836-2845	expertise	person[155]|abstract|abstract[157]	new[155]|giv|giv[157]	_	_
18-16	2846-2849	and	person[155]|abstract[157]	new[155]|giv[157]	_	_
18-17	2850-2858	interest	person[155]|abstract[157]|abstract[158]	new[155]|giv[157]|giv[158]	_	_
18-18	2859-2861	in	person[155]|abstract[157]|abstract[158]	new[155]|giv[157]|giv[158]	_	_
18-19	2862-2865	the	person[155]|abstract[157]|abstract[158]|abstract[159]	new[155]|giv[157]|giv[158]|new[159]	ana	18-26[0_159]
18-20	2866-2877	cytobiology	person[155]|abstract[157]|abstract[158]|abstract[159]	new[155]|giv[157]|giv[158]|new[159]	_	_
18-21	2878-2880	of	person[155]|abstract[157]|abstract[158]|abstract[159]	new[155]|giv[157]|giv[158]|new[159]	_	_
18-22	2881-2886	human	person[155]|abstract[157]|abstract[158]|abstract[159]|animal[161]|animal[162]	new[155]|giv[157]|giv[158]|new[159]|giv[161]|giv[162]	coref	18-22[162_161]
18-23	2887-2890	PCa	person[155]|abstract[157]|abstract[158]|abstract[159]|abstract|animal[161]|animal[162]	new[155]|giv[157]|giv[158]|new[159]|giv|giv[161]|giv[162]	_	_
18-24	2891-2896	cells	person[155]|abstract[157]|abstract[158]|abstract[159]|animal[161]|animal[162]	new[155]|giv[157]|giv[158]|new[159]|giv[161]|giv[162]	_	_
18-25	2897-2900	and	person[155]|abstract[157]|abstract[158]|abstract[159]|animal[162]	new[155]|giv[157]|giv[158]|new[159]|giv[162]	_	_
18-26	2901-2904	its	person[155]|abstract[157]|abstract[158]|abstract[159]|animal[162]|abstract|abstract[164]	new[155]|giv[157]|giv[158]|new[159]|giv[162]|giv|giv[164]	_	_
18-27	2905-2913	clinical	person[155]|abstract[157]|abstract[158]|abstract[159]|animal[162]|abstract[164]	new[155]|giv[157]|giv[158]|new[159]|giv[162]|giv[164]	_	_
18-28	2914-2926	applications	person[155]|abstract[157]|abstract[158]|abstract[159]|animal[162]|abstract[164]	new[155]|giv[157]|giv[158]|new[159]|giv[162]|giv[164]	_	_
18-29	2927-2928	.	_	_	_	_
